Home > Healthcare > Medical Devices > Medical Supplies > Breast Cancer Core Needle Biopsy (CNB) Market

Breast Cancer Core Needle Biopsy (CNB) Market Trends

Report ID: GMI11100
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Breast Cancer Core Needle Biopsy Market Trends

Growing awareness and screening programs are expected to drive market demand for breast cancer core needle biopsy (CNB) by increasing the number of women undergoing regular breast cancer screenings. Public health campaigns and educational initiatives have highlighted the importance of early detection, leading to more women seeking diagnostic procedures.

For instance, in December 2022, Fujifilm India Pvt Ltd hosted an event in Bhubaneshwar, Odisha, to emphasize the importance of early breast cancer detection through advanced digital mammography. The event featured the AMULET Innovality with CEDM technology at NIDAN Diagnostic, aiming to enhance diagnostic accuracy. This innovative tool supports earlier detection, potentially reducing late-stage diagnoses and treatment complexities.
This promotional focus on early diagnosis and screening programs is expected to increase the number of diagnostic procedures, thereby boosting demand for CNB and fostering overall market growth.
Additionally, the need for ongoing monitoring and assessment of cancer patients further expands the market, as repeat biopsies become essential for effective treatment management.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Breast cancer core needle biopsy industry size was valued USD 776.5 million in 2023 and will grow at a 7.8% CAGR between 2024 and 2032, fueled by rising breast cancer incidence and increased awareness of early detection.

Breast cancer CNB industry from the ultrasound-guided segment will achieve 7.6% CAGR through 2032, driven by its precision and real-time imaging capabilities.

U.S. breast cancer core needle biopsy industry size was USD 320.3 million in 2023, attributed to its advanced healthcare infrastructure and high incidence of breast cancer.

Aurora Imaging Technology Inc., BD, Devicor Medical Products, Inc., Fujifilm Holdings, Hologic, Inc., Insight Medbotics, McLaren, Rye Radiology, Siemens Healthcare Private Limited, and Sentinelle Medical Inc, among others.